Mi Cai, Ph.D.

Technology Specialist, Registered Patent Agent - Boston

Mi Cai
Download Media Photo

Contact Information

617.832.1121

617.832.7000

mcai@foleyhoag.com Download vCard

Mi Cai is a technology specialist and registered patent agent in Foley Hoag's Intellectual Property Department. She assists in preparation and prosecution of U.S. and foreign patent applications in the areas of biotechnology and pharmaceuticals.

Dr. Cai has a strong background in molecular cell biology, and extensive research experience in stem cell, genome editing and small molecule drug discovery.

More ยป

Education:

  • Washington University in St. Louis, Ph.D., Molecular Cell Biology, 2012
  • Peking University, B.S., Biological Sciences, 2006

Languages:

English, Chinese

Professional Experience

  •  Senior Scientist, Pfizer, Cambridge, MA
  • Co-author, “DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells,” Nature Chemical Biology 10(8): 623-625 (2014)
  • First author, “Targeted genome editing tools for disease modeling and gene therapy,” Current Gene Therapy 14(1): 2-9 (2014)
  • First author, “Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation,” Blood 120(2): 335-46 (2012)
  • Co-author, “Snail promotes the cell-autonomous generation of Flk1+ endothelial cells through the repression of the microRNA-200 family,” Stem Cells and Development 21(2): 167-76 (2012)
  • Co-author, “Snail and the microRNA-200 family act in opposition to regulate epithelial-to-mesenchymal transition and germ layer fate restriction in differentiating ESCs,” Stem Cells 29(5): 764-76 (2011)
  • Co-author, “Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs,” Cell Stem Cell 3(1): 55-68 (2008)
  • Co-first author, “Development of a microscopy-based assay for protein kinase Czeta activation in human breast cancer cells,” Analytical Biochemistry 362(1): 8-15 (2007)
  • Lecturer, “Gene editing in drug discovery and disease modeling,” the 13th Annual Discovery on Target Short Course: A Primer to Gene Editing: Tools and Applications, Boston (2015)
  • Speaker, “Applications of CRISPR-Cas9 gene editing to drug target validation,” the IBC’s Genome Editing Applications Conference: Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs, AAVs and other Genome Engineering Technologies, Boston (2015)
Add to Bio Folder

Download Bio

Court Admissions

  • U.S. Patent & Trademark Office (Agency)